Skip to main content
Evidence Snapshot

Serine/threonine-protein kinase ULK3

CHEMBL5047 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:52:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5047
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase ULK3 as ChEMBL target CHEMBL5047, mapped to UniProt Q6PHR2. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase ULK3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5047
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q6PHR2
Serine/threonine-protein kinase ULK3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serine/threonine-protein kinase ULK3 matters

As of 2026-09-13

Serine/threonine-protein kinase ULK3 is reviewed as Serine/threonine-protein kinase ULK3 (UniProt Q6PHR2); the current evidence base includes 17 approved drugs, 705 compounds, and 196 assays, with lead potency reaching pChEMBL 8.9.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 17 approved drugs, 705 compounds, and 196 assays for this target. The dominant activity type is KD. CHEMBL388978 is the current potency anchor at pChEMBL 8.9.

Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 8.9).

Activity source · ChEMBL 36 via Core Engine
17 approved pChEMBL 8.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serine/threonine-protein kinase ULK3 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q6PHR2, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

705
Total Compounds
196
Total Assays
17
Approved Drugs
IC50: 16.0, KD: 330.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL388978
 8.9 IC50 —
No preferred name
CHEMBL388978
 8.9 Kd —
No preferred name
CHEMBL603469
 8.3 Kd Clinical
No preferred name
CHEMBL3301622
 8.2 Kd Approved
No preferred name
CHEMBL475251
 8.2 Kd Clinical

Approved Drugs

Structure Compound First Approval
MOMELOTINIB
CHEMBL1078178
 2023
FEDRATINIB
CHEMBL1287853
 2019
GILTERITINIB
CHEMBL3301622
 2018
NINTEDANIB
CHEMBL502835
 2014
BOSUTINIB
CHEMBL288441
 2012
AXITINIB
CHEMBL1289926
 2012
SUNITINIB
CHEMBL535
 2006
ERLOTINIB
CHEMBL553
 2004
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:52:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5047